On October 28th, Sanofi US announced that the company is taking the precautionary measure of voluntarily recalling ALL Auvi‐Q® (epinephrine injection, USP) currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers.

In an effort to help you communicate information concerning the recall to your customers we have attached a letter highlighting the details of the recall.

If you have any additional questions regarding the Auvi‐Q recall please contact your Sanofi US Sales Representative.

At Sanofi US, we value our customers and sincerely regret any inconvenience this may have caused.

For more information from Sanofi - https://www.auvi-q.com/